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Abstract
Background: Pain is common in head and neck cancer (HNC) patients and may be attributed to
the malignancy and/or cancer treatment. Pain mechanisms and patient report of pain in HNC are
expected to include both nociceptive and neuropathic components. The purpose of this study was
to assess the trajectory of orofacial and other pain during and following treatment, using patient
reports of neuropathic pain and nociceptive pain and pain impact.
Methods: 124 consecutive HNC patients receiving radiation therapy (RT) (95 men, 29 women;
mean age: 54.7 ± 12.3 years) participated in a patient-reported outcome (PRO) assessment.
Patients completed the McGill Pain Questionnaire three times during therapy and 3 months
following study entry.
Results:  The majority of patients related their pain to the tumor and/or cancer treatment.
Whereas 59% reported their pain to be less severe than they expected, 29% were not satisfied with
their level of pain despite pain management during cancer therapy. Worst pain was 3.0 ± 1.3 on a
0- to 5-point verbal descriptor scale. Pain intensity was present at entry, highest at 2-week follow-
up, declining towards the end of treatment and persisting at 3-month follow-up. The most common
neuropathic pain descriptors chosen were aching (20%) and burning (27%); nociceptive words
chosen were dull (22%), sore (32%), tender (35%), and throbbing (23%), and affective/evaluative
descriptors were tiring (25%) and annoying (41%). 57% of patients reported continuous pain, and
combined continuous and intermittent pain was reported by 79% of patients.
Discussion: This study provides evidence that patients with HNC experience nociceptive and
neuropathic pain during RT despite ongoing pain management. The affective and evaluative
descriptors chosen for head and neck pain indicate considerable impact on quality of life even with
low to moderate levels of pain intensity. These findings suggest that clinicians should consider
contemporary management for both nociceptive and neuropathic pain in head and neck cancer
patients.
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Background
Pain is common for the 35,310 people who are diagnosed
with head and neck cancer (HNC) in the United States
annually [1,2]. HNC pain may arise due to tissue damage
from multiple sources such as mucosal injury, invasion of
the tumor into somatic tissue (skin, muscle, bone) with
inflammation or ischemia, and nerve infiltration or com-
pression [3]. Treatment for HNC involves single or multi-
modal therapy employing surgery, chemotherapy (CT)
and/or radiation (RT), all of which can damage somatic
tissues and nerves. These multiple sources of somatic tis-
sue and neural damage from the tumor and cancer treat-
ment result in pain being experienced by all HNC patients
[4].
Neuropathic pain is defined by The International Associa-
tion for the Study of Pain (IASP) as pain initiated or
caused by a primary lesion or dysfunction in the nervous
system resulting in debilitating pain [5]. Damage to
somatic and primary and/or central neurons commonly
associated with nociceptive pain may result in neuro-
pathic pain [6-8]. This dysfunction in the nervous system
may be exacerbated by persistent unrelieved nociceptive
pain associated with the tumor or cancer treatments (e.g.,
mucositis), thereby producing neuropathic pain. Altera-
tion in pain processing at peripheral sites (such as with
mucositis) and central levels (that may occur when
mucositis pain is persistent) produces characteristic sen-
sory abnormalities such as hyperalgesia and allodynia [9].
Hyperalgesia is defined as an increased response to a stim-
ulus that is normally painful and allodynia as pain due to
a stimulus that does not normally provoke pain [8].
One of the most feared consequences of cancer is the pos-
sibility of severe and uncontrolled pain in patients with
advanced cancer [10]. In patients with HNC, pain is
reported in up to 85% of cases at diagnosis [11,12]. Pain
due to soft tissue and bone destruction and nerve injury
may involve inflammatory and/or neuropathic mecha-
nisms [13-19]. Further, it is estimated that 45% to 80% of
all cancer patients have inadequate pain management
[20-22]. Barriers to adequate pain management include
patients' reluctance to report pain [23], current pain man-
agement practices by health care providers [24] and pro-
viders' negative ideas about and regulatory barriers to the
use of opioids [25]. In addition, limited understanding of
the frequency and role of neuropathic pain mechanisms
and the lack of use of management approaches for neuro-
pathic pain may compromise symptom management in
cancer patients.
Cancer pain causes increased morbidity, reduced perform-
ance status, increased anxiety and depression, and dimin-
ished quality of life (QOL) [17,26-28]. Head and neck
and oral pain management may be particularly challeng-
ing due to the rich innervation of the orofacial region and
because oral intake, swallowing, speech and other motor
functions of the head and neck and oropharynx are con-
stant pain triggers. In addition, the oral mucosa is suscep-
tible to the effects of systemic chemotherapy and regional
radiotherapy, resulting in painful mucositis. The oral
microbial flora may cause secondary infection with
attendant pain and morbidity.
Pain may be the first symptom in 20% to 50% of all can-
cer patients [10] due to the malignancy, and oral pain may
arise from HNC in up to 85% [10,11] from metastatic dis-
ease in the head and neck or due to oral involvement in
systemic cancers (e.g., leukemia). In a recent study, inves-
tigators identified pain in 56% of patients with HNC at
diagnosis, and found mixed nociceptive and neuropathic
pain in 93% of those with pain [29]. In a retrospective
study of 1,412 patients with oral cancer, pain was identi-
fied as the first sign of cancer in 19%, and pain was com-
monly reported with tumor recurrence [30]. Others
reported cancer-related pain in 52% of hospitalized
patients, with pain directly due to tumor in 29% and to
surgery in 50% [31,32]. In large surveys of pain character-
istics in cancer including HNC [17,19], patients suffered
pain associated with the tumor (87% to 92.5%), or cancer
therapy (17% to 20.8%) or both. In HNC, 78% of patients
report pain in the head, face or mouth and 54% in the cer-
vical region or shoulder [19]. In HNC, pain is the major
reason (up to 85%) for seeking care [33], but at diagnosis
pain is usually of low intensity (mean 10-cm visual ana-
logue scale [VAS] = 3). Orofacial pain associated with can-
cer management is a well-recognized adverse effect of
treatment, but whether this represents nociceptive or neu-
ropathic mechanisms is not well defined. Pain due to oral
mucositis is the most frequently reported patient-related
complaint impacting QOL during cancer therapy [34-42]
and often results in severe pain for which opioid analge-
sics are prescribed [38,43-45], sometimes with additional
impaired QOL. Successful pain management requires
knowledge of, and attention to, multiple pain mecha-
nisms that may culminate in the patient's pain.
In HNC patients, neuropathic pain has not been well
characterized in terms of sensory report (location, inten-
sity, quality and pattern) or sensory quantification (allo-
dynia and hyperalgesia). Grond et al. [46] reported that
30% of HNC patients suffered from neuropathic pain as
result of the cancer or its treatments. In addition to neuro-
plasticity as a mechanism for neuropathic pain, other
mechanisms may play a role in producing neuropathic
pain associated with mucositis that may be conditioned
by inflammatory mediators (e.g., tumor necrosis factor-
alpha [TNF-α]), which play a central role in the activation
of cytokines and are elevated in mucositis [47]. TNF-α is
known to be involved in mediation of neuropathic painHead & Neck Oncology 2009, 1:26 http://www.headandneckoncology.org/content/1/1/26
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and hyperalgesia [48]. Other chemical mediators impli-
cated in neuropathic pain include reactive oxygen/nitro-
gen species, bradykinin, substance P and other cytokines
that are upregulated in mucositis [47]. Investigators also
have demonstrated changes in dorsal horn processing of
nociceptive stimuli that result in neuropathic pain [49].
These mechanisms may result in neuropathic pain associ-
ated with tissue damage that occurs from HNC or its treat-
ment. Previous investigators have not characterized the
pain in HNC patients using multidimensional pain meas-
ures. The purpose of this paper is to describe the experi-
ence and trajectory of sensory pain (location, intensity,
quality, and pattern) in patients with HNC undergoing
cancer treatment using PRO, including neuropathic and
nociceptive pain descriptors.
Methods
We conducted a 3-month repeated-measures study to
describe the trajectory of pain and pain descriptors in con-
secutive patients with HNC. The study was approved by
the Institutional Review Board at the University of Wash-
ington for initial data collection and at the University of
Illinois at Chicago for ongoing data analysis.
Sample
Eligible subjects: (a) had a diagnosis of HNC; (b) spoke
and read English; and (c) had pain related to the cancer or
to cancer therapy during the week prior to enrolling.
Patients were excluded if they: (a) had surgery within one
month; (b) were physically unable to complete study pro-
cedures; or (c) were mentally unable to complete study
questionnaires because of brain metastases or develop-
mental problems, as measured by a Mini-Mental State
Exam (MMSE) [50] (defined as a score of 20 or less). The
MMSE is an 11-question scale designed to efficiently
screen a person's cognitive functioning. Scores 19 and
below represent cognitive impairment [50].
Of the 151 patients eligible for the study, 27 refused and
124 consecutive patients participated (Table 1). The par-
ticipants included 95 men and 29 women. Their mean age
was 54.7 ± 12.3 years. Most of the participants were Cau-
casian (88%), with 3% Hispanic and 2% African Ameri-
can. Other demographics of the patients are shown in
Table 1. The primary tumor site was oral cavity/orophar-
ynx (46%), major salivary gland (23%), maxillary sinus
(12%), larynx (11%), and unknown (8%). The tumor
stage at enrollment was Stage I in 17%, Stage II in 14%,
Stage III in 14% and Stage IV in 46%; 10% were unknown
primary. The histologic diagnoses were: adenocarcinoma
(13%); adenoid cystic carcinoma (31%); mucoepider-
moid carcinoma (13%); squamous cell carcinoma (37%);
and miscellaneous (7%). Most (68.5%) patients had sur-
gery prior to radiation therapy.
Procedures
Medical and dental providers in the cancer clinic intro-
duced patients to the investigators in person. A research
team member informed patients about the study and
scheduled data collection to coincide with a scheduled
clinic appointment if patients were eligible and agreed to
participate. The researcher obtained a signed informed
consent, administered the MMSE to confirm eligibility,
and interviewed the patient to complete a demographic
data form. Patients were seen by their oncology providers
for routine clinic follow-up visits. After the clinic visit,
patients completed the valid and reliable 1970 version of
the McGill Pain Questionnaire [51] at 2 weeks, 4 weeks
and 3 months after the baseline measures to record pain
in the extra-oral and intra-oral environments. Pain loca-
tion was measured as the number of pain sites marked on
a body outline. Pain intensity was measured as current,
least, and worst pain using the 0–5 verbal descriptor scale.
Pain quality was measured as descriptors selected from a
list of 78 that represented sensory (PRI-S), affective (PRI-
A), evaluative (PRI-E), miscellaneous (PRI-M), and total
(PRI-T) pain, as well as number of words chosen (NWC)
[52-54]. Pain pattern was measured as descriptors selected
from a list of nine words representing continuous, inter-
mittent, and brief patterns of pain. The following infor-
mation was recorded from interview or medical record
review: (1) gender; (2) age; (3) diagnosis(es); (4) medica-
tion(s) taken, including systemic and topical anesthetics
and analgesics and time of last dose; and (5) RT dose and
CT agent(s).
Research staff members entered data in CRUNCH4
(Crunch Software Corporation, San Francisco, CA) and
exported it to SPSS (SPSS, Inc., Chicago, IL) for data anal-
ysis. We present descriptive statistics for the pain location,
intensity, quality, and pattern, as well as the number of
nociceptive and neuropathic descriptors reported at each
measurement time point. Pain quality findings are
reported for the first pain site reported that was located in
the head and neck region. We plotted scores and calcu-
lated repeated-measures ANOVAs over time for pain
scores reported during the 3-month study.
Results
Patient characteristics are shown in Table 1. Cancer ther-
apy delivered was radiation therapy alone (n = 21; 17%),
a combination of surgery and radiation therapy (n = 70;
57%), a combination of chemotherapy and radiation
therapy (n = 17; 14%), or a combination of surgery, radi-
ation and chemotherapy (n = 14; 11%).
Prior to study entry, the majority of patients reported pain
for 0–6 months (77%), 7–12 months (5.6%), 13–23
months (4%), or more than 2 years (12.9%). At baseline,
patients associated their pain with their cancer (21%), sur-Head & Neck Oncology 2009, 1:26 http://www.headandneckoncology.org/content/1/1/26
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gery (53.2%), or both tumor and surgery (20.5%). On
average, patients reported 2.1 ± 2.2 pain sites. Pain meas-
ures at baseline are shown in Table 2. The distributions of
the pain locations are presented for the first site marked
and for all sites marked (Table 3). The neuropathic, noci-
ceptive, affective, and evaluative pain descriptors are
shown in Table 4.
The pain intensity scores presented in Table 2 indicate that
the average pain intensity was mild and continued despite
pain management interventions, yet 29% of the patients
were not satisfied with their level of pain. Head and neck
and oral were the most common sites of pain during RT
(79% of patients). On average, patients selected 1.5 ± 1.8
neuropathic words (min = 0, max = 9), with burning
selected as the most common descriptor (21%). They
selected 1.8 ± 2.1 nociceptive words (min = 0, max = 14),
and the most common were tender (26.6%), soreness
(25%), and throbbing (20.2%). Affective pain quality
descriptors selected were: tiring (22.6%), nagging
(17.7%), nauseating (7.3%) and exhausting (7.3%). Eval-
uative descriptors were: annoying (35.5%), troublesome
(8.9%), and miserable (8.9%). The average PRI-T was
13.5 ± 11.3. Patients reported their pain pattern was con-
stant (65.5%), intermittent (57.3%), and/or transient
(33.1%) (Figure 1).
Pain scores decreased from admission to last follow-up.
ANOVA showed significant decreases in the pain meas-
ures over the 4 time points: the number of the neuro-
pathic words chosen (F(3,222) = 48.5, p  < 0.001); the
number of the nociceptive words chosen (F(3,222) = 51.2,
p < 0.001) (Figure 2); PRI-S (F(3,222) = 11.9, p < 0.001);
PRI-A (F(3,222) = 1.5, p < 0.21); PRI-E (F(3,222) = 3.5, p <
Table 1: Demographic characteristics of enrolled subjects (N = 124)
Variable Category Frequency (n) Percent
Gender Male 95 77%
Female 29 23%
Education <= 8th grade 3 2%
12th grade 54 44%
Associated degree 32 26%
>= Bachelor's degree 30 24%
Missing 5 4%
Ethnicity Caucasian 109 88%
African American 3 2%
Hispanic 4 3%
Asian 3 2%
Other 5 4%
Cancer Stage (Current) Stage I 22 18%
Stage II 17 14%
Stage III 15 12%
Stage IV 62 50%
Missing 8 6.5%
Surgery No 38 31%
Yes 85 69%
Missing 1 1%
Chemotherapy No 91 73%
Yes 31 25%
Missing 2 2%
Radiation Therapy Yes 124 100%
Origin of Pain Tumor-related 26 21%
Treatment-related 66 53%
Both 24 19%
Unknown 8 6%Head & Neck Oncology 2009, 1:26 http://www.headandneckoncology.org/content/1/1/26
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Table 2: Pain measures at baseline
Variable Category Frequency (n) % Mean SD Min/Max
Pain expectation Worse than expected 18 15
The same as expected 28 23
Not as bad as expected 65 59
Satisfied with Pain Level No 36 29
Yes 80 65
Missing 8 7
Current pain (0–5) 1.51 1.01 0–5
Worst pain (0–5) 3.03 1.26 0–5
Least pain (0–5) 0.76 0.74 0–3
Number of pain sites 2.1 2.2 0–16
Pain Rating Index Sensory 9.1 7.3 0–34
Affective 1.0 1.7 0–8
Evaluative 1.2 1.5 0–5
Miscellaneous 2.1 2.9 0–15
Total 13.5 11.3 0–58
Number of Words Chosen 5.9 4.1 0–20
Pain Pattern Continuous 41 33.1%
Intermittent 18 14.5%
Brief 2 1.6%
Continuous/Intermittent 16 12.9%
Continuous/Brief 2 1.6%
Intermittent/Brief 26 21%
Continuous/Intermittent/Brief 11 8.9%
Missing 8 6.4%
Table 3: Frequency of pain location areas as marked on a body outline for the first site marked and for all pain sites (ranged from 1 to 
6 pain sites for each of the 124 participants)
Pain Location Area Frequency for first site marked Frequency for all 6 pain sites marked
Head (head, neck, face, chin, gum/tongue, chin, mouth) 98 101
Arm (arm, shoulder, elbow, hand) 3 12
Chest (chest, breast) 0 3
Abdomen 1 11
Leg (leg, knee, foot) 0 3
Back (back, spine) 3 6
Buttock (buttock, hip, anus) 0 6
Missing/unknown 19 0Head & Neck Oncology 2009, 1:26 http://www.headandneckoncology.org/content/1/1/26
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Table 4: Frequency of pain quality descriptors attributed to head and neck pain site
Neuropathic Descriptor Frequency (%) Nociceptive Descriptor Frequency (%) Affective and Evaluative 
Descriptors
Frequency (%)
Aching 25 (20.2%) Beating 4 (3.2%) Fearful 5 (4.0%)
Boring 7 (5.6%) Cramping 0 (0%) Frightening 3 (2.4%)
Burning 33 (26.6%) Crushing 3 (2.4%) Terrifying 0 (0%)
Cold 0 (0%) Cutting 4 (3.2%) Grueling 4 (3.2%)
Cool 1 (0.8%) Dull 27 (21.8%) Punishing 3 (2.4%)
Drawing 1 (0.8%) Gnawing 6 (4.8%) Cruel 0 (0%)
Drilling 3 (2.4%) Heavy 2 (1.6%) Vicious 2 (1.6%)
Flashing 5 (4.0%) Hurting 16 (12.9%) Killing 1 (0.8%)
Flickering 10 (8.1%) Lacerating 5 (4.0%) Tiring 31 (25%)
Freezing 1 (0.8%) Piercing 11 (8.9%) Exhausting 10 (8.9%)
Hot 9 (7.3%) Pinching 2 (1.6%) Wretched 2 (1.6%)
Itchy 0 (0%) Pounding 2 (1.6%) Blinding 1 (0.8%)
Jumping 4 (3.2%) Pressing 13 (10.5%) Sickening 0 (0%)
Lancinating 1 (0.8%) Pulling 0 (0%) Suffocating 2 (1.6%)
Numb 14 (3.2%) Pulsing 9 (7.3%) Annoying 51 (41.1%)
Penetrating 1 (0.8%) Rasping 10 (8.1%)
Pricking 2 (1.6%) Sharp 19 (15.3%)
Quivering 4 (3.2%) Sore 40 (32.3%)
Radiating 1 (0.8%) Splitting 4 (3.2%)
Scalding 2 (1.6%) Squeezing 3 (2.4%)
Searing 4 (3.2%) Taut 8 (6.5%)
Shooting 9 (7.3%) Tearing 6 (4.8%)
Smarting 7 (5.6%) Tender 43 (34.7%)
Spreading 2 (1.6%) Throbbing 29 (23.4%)
Stabbing 11 (8.9%) Tugging 3 (2.4%)
Stinging 0 (0%) Wrenching 0 (0%)
Tight 0 (0%)Head & Neck Oncology 2009, 1:26 http://www.headandneckoncology.org/content/1/1/26
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0.02); PRI-M (F(3,222) = 2.6, p < 0.05); PRI-T (F(3,222) =
9.2, p < 0.001) (Figure 3); and total NWC (F(3,222) = 8.7, p
< 0.001).
Current pain at visit one was 1.51 ± 1.01, worst pain was
3.03 ± 1.26; those increased at time 2, where current pain
was 1.60 ± 0.81 and worst was 3.18 ± 1.15, and decreased
at subsequent time points. The scores for current and
worst pain, pain pattern, and number of pain sites were
not significantly different by the type of cancer therapies
that the patient received. The subjects with both chemo-
therapy and radiation treatments reported statistically sig-
nificant higher PRI-T scores (mean, 19.58 vs. 12.56, t = -
2.29, p < .024 than the subjects with other therapies (e.g.,
radiation only, surgery and radiation; or chemotherapy,
radiation and surgery). At time 3, worst pain was 2.89 ±
1.23, and at time 4 worst pain was 2.54 ± 1.40, current
pain 1.02 ± 1.07 and least pain 0.60 ± 0.81 (Figure 4). A
highly correlated linear trend was seen between the
number of nociceptive and neuropathic words chosen
during treatment. Patient demographics, including age,
gender, ethnicity and income, did not correlate with the
variables assessed.
These reports of pain continued despite use of analgesics
and adjuvant drugs for pain management during and fol-
lowing cancer therapy. Of these patients, 10.5% were tak-
ing step 1 analgesics (NSAIDs and non-opioids), 21%
adjuvant analgesics, 8.1% step 2 opioids (for mild to
moderate pain intensity), 20.2% step 3 opioids (for mod-
erate to severe pain intensity). The other patients were tak-
ing combinations of analgesics and adjuvant drugs: 8.9%
adjuvant and step 1 analgesics; 3.2% adjuvant and step 2
opioids; 4% adjuvant and step 3 opioids; 6.5% step 1 and
step 2 opioids; 1.6% step 2 and step 3 opioids; 1.6% adju-
vant, step 1, and step 2 opioids; 0.8% adjuvant, step 1 and
step 3 opioids; and 11% were missing analgesic drug data.
We estimated adequacy of analgesic prescription by calcu-
lating a pain management index (PMI) as suggested by
Cleeland [55,56]. We subtracted the worst pain level score
from the analgesics step score to produce a PMI score. A
negative PMI score indicated inadequate analgesic pre-
Tingling 12 (9.7%)
Min = 0 Min = 0 Min = 0
Max = 11 Max = 15 Max = 13
Mean = 2.5 Mean = 2.9 Mean = 2.2
SD = 2.3 SD = 2.5 SD = 2.4
Table 4: Frequency of pain quality descriptors attributed to head and neck pain site (Continued)
Frequencies of Each Pain Pattern Descriptor (%) Figure 1
Frequencies of Each Pain Pattern Descriptor (%).
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scription (under-treatment of pain) and 0 or positive PMI
scores indicated satisfactory analgesics. Based on Clee-
land's PMI, 63.7% of the patients were taking prescrip-
tions satisfactory for their pain intensity level; 23.4% were
taking prescriptions that represented undertreatment for
the level of their pain intensity. PMI scores could not be
calculated for those for whom drug data were missing.
Discussion
HNC patients were enrolled in the study during cancer
treatment when pain was reported. Patients attributed
their pain to the cancer, prior surgical treatment or the
ongoing radiation therapy for HNC. Pain was discomfort-
ing on average at entry (worst pain intensity 3.0 ± 1.3),
and it was less than anticipated in more than half of the
patients, as expected in about one-fifth and worse than
expected by some. In our survey, pain was reported first in
the head and neck or oral cavity by 79% (n = 98) of the
participants.
In a previous study, pain was reported by patients with
oral squamous cell carcinoma at presentation in 39% of
138 cases and correlated with tumor stage [57]. Pain at
diagnosis of HNC has been variable, with pain reported in
Mean Number of Neuropathic and Nociceptive Words Figure 2
Mean Number of Neuropathic and Nociceptive Words.
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up to 85% of patients [58]. Investigators of one study
found that 65.5% of 1,070 cancer patients reported pain
prior to cancer therapy, whereas pain was less common at
diagnosis in another study (48.1%) [59,60]. In a recent
study, pain was identified in 56% of patients with HNC at
diagnosis [29]. Pain at diagnosis is typically of low inten-
sity discomfort as the first symptom leading to diagnosis
[58]. The most common qualitative descriptions of pain
were aching, dull, or pressing [33]. Interestingly, patients
who present with pain before treatment develop signifi-
cantly higher impairment scores due to pain during and
following treatment [59], suggesting that sensitization
occurs. We found similar findings in our trial, where
report of nociceptive and neuropathic pain at entry pre-
dicted pain experience during and following therapy.
Neuropathies are commonly reported in patients with
malignancy (1.7%–5.5%) and may be due to direct effects
of the tumor, paraneoplastic syndromes and/or treat-
ment-related toxicity [61-64]. Neurotoxicity is increased
in patients with pre-existing nerve damage [65] and with
nutritional deficiencies [66]. However, the incidence of
paraneoplastic neuropathies occurring in the orofacial
region is unclear. In our survey, neuropathic descriptors of
pain were selected by a total of 73% of subjects (n = 91),
suggesting that neuropathic pain is common in patients
with HNC. In a previous study, mixed nociceptive and
neuropathic descriptors were chosen by 93% of HNC
patients reporting pain at diagnosis [29]. The affective and
evaluative impact of pain in head and neck and oral sites
in these patients indicates the significant impact of head
and neck pain, in which neuropathic mechanisms are
common. The finding of a linear trend in the number of
nociceptive and neuropathic words chosen during treat-
ment suggests that the pain experience may be due to both
nociceptive and neuropathic pain. Patient demographics,
including age, gender, ethnicity and income, did not cor-
relate with the variables assessed. Approximately one-
third of patients reported continuous pain, 40% reported
continuous plus intermittent pain and 15% reported
intermittent pain associated with oral function such as
with eating or swallowing. We did not identify a shift
from neuropathic and nociceptive word choice during
treatment, suggesting that both mechanisms are associ-
ated with pain at entry and during RT.
The most common acute oral side effect of chemotherapy
and radiotherapy is oral mucositis [67]. Oral mucositis
and associated pain is reported to be the most distressing
symptom in radiotherapy, with increasing pain intensity
and pain interference scores by week 3, peaking at week 5
[68] and persisting for weeks following irradiation [35].
Mucositis pain is common (58%–75%) and interferes
with daily activities in approximately one-third of subjects
[69-74] and with social activities and mood in 50%–60%
[35]. Combined chemotherapy and radiation therapy
results in increased frequency, severity and duration of
mucositis [73-76]. These findings were reflected in the
pain report of subjects in this study, where pain intensity
remained essentially unchanged during RT despite use of
analgesics and other pain management. In addition to
mucositis, some cytotoxic agents may cause jaw pain and
neuropathy (e.g., vincristine, vinblastine, platinum).
Surgical procedures commonly result in acute nociceptive
orofacial pain and establish conditions that may lead to
Mean Scores for Current, Least, and Worst Pain Intensity at Baseline, 2 weeks, 4 weeks, and 3 months (0–5 scale) Figure 4
Mean Scores for Current, Least, and Worst Pain Intensity at Baseline, 2 weeks, 4 weeks, and 3 months (0–5 
scale).
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painful post-surgical neuropathy. In addition to tissue
injury at tumor resection, morbidity is increased by con-
comitant procedures such as radical neck dissection [77].
In this study, patients reported that pain was related to the
tumor (21%), and related to cancer treatment (53.2%) or
both (20.5%), indicating that patients felt that the major-
ity of pain was treatment-related. Resection of the mandi-
ble inevitably leads to sensory impairment [78], with 50%
of recipients experiencing regional hyperalgesia or allody-
nia. At 2–5 years post maxillectomy, 88%–90% of
patients reported persistent pain [79]. In an analysis of
patients treated for laryngeal cancer, ablative surgery with
adjuvant chemo- and/or radiotherapy was associated with
increased chronic pain and psychosocial morbidity com-
pared to that of patients treated by chemoradiation alone
[80], underscoring the impact of surgical intervention.
Investigators of another study, examining pain scores fol-
lowing HNC surgery, showed that the highest scores were
for the oral cavity, followed by the larynx, oropharynx and
nasopharynx [79]. In a large survey of surgically treated
oral cancer patients, functional problems were reported
postoperatively in more than 50% of cases [60]. At review
(= 6 months post-surgery), impairment due to moderate
to severe pain was found in 34.3% of cases [60]. In two
studies, the most frequent pain locations were the shoul-
der (31%–38.5%), neck (4.9%–34.9%), TMJ (4.9%–
20.1%), oral cavity (4.2%–18.7%) and the face and other
head regions (4.2%–15.6%) [60,81], reflecting morbidity
secondary to surgical management [77,82]. Fortunately,
there is a tendency for post-treatment symptoms to
improve with time [83]. By 60 months post surgery, a
smaller proportion of patients (14.9%) (n = 74) had per-
sisting pain [81]. In cancer patients, the postoperative
pain experience typically is characterized by acute pain
persisting 1–2 months, with a gradual improvement over
time [83-85]. However, long-term HNC survivors (> 3
years) still suffer significantly more pain and functional
problems than matched control subjects, even though
there is a relative return towards normal function
[81,83,85]. Persisting pain following surgery may involve
inflammatory and neuropathic pain mechanisms,
depending on the extent of surgery and its anatomic loca-
tion. Functional consequences are often secondary to pain
and may involve wound contractures and scarring [81].
Our study provides evidence that patients with HNC expe-
rience nociceptive and neuropathic pain. These findings
are supported in prior studies, where 30% of HNC
patients suffered from neuropathic pain in one study [46],
and the majority of patients reported pain in another
study [29].
The affective and evaluative descriptors chosen for head
and neck pain indicate considerable impact on quality of
life, even with low to moderate levels of pain intensity.
Effective management requires accurate diagnosis of the
multifaceted etiology of orofacial pain in cancer patients
[47,86]. Pain intensity scores did not progress during
treatment with ongoing pain management and were
lower than at entry at the final assessment visit following
RT. The findings suggest that expert medical management
during cancer therapy can modulate the pain experience,
despite the impact of radiation and chemotherapy. The
PMI indicated that 63.7% of the patients were taking pre-
scriptions satisfactory for their pain intensity level, while
23.4% were not adequately treated for their pain level;
10.5% of patients were on step 1 analgesics (non-opioid
analgesics), 8.1% step 2 opioid (mild opioids), 20.2%
step 3 opioids and 21% prescribed adjuvant analgesics.
The other patients were using combinations of analgesics
and adjuvant drugs.
Nociceptive pain is managed with treatment of the cause
and topical anesthetics and analgesics, with reliance upon
systemic analgesics. Neuropathic pain is typically more
difficult to manage and in contrast relies upon locally act-
ing anesthetics and centrally acting antidepressant and
anti-convulsant medications, along with biopsychosocial
treatment and systemic analgesics. Future research regard-
ing pain in head and neck cancer patients should consider
neuropathic and nociceptive pain-related complaints
along with quantitative sensory testing to confirm neuro-
pathic pain. In clinical practice, clinicians should consider
contemporary management for both nociceptive and neu-
ropathic pain in head and neck cancer patients.
Conclusion
Pain experienced during radiation therapy for head and
neck cancer is common. Neuropathic pain descriptors
were chosen by 73% of patients and a linear trend was
seen in number of neuropathic and nocicpetive descrip-
tors chosen by pateints during therapy. Pain was common
despite ongoing pain management during therapy. This
study shows that pain during radiation therapy have both
nocicpetive and neeuropathic qualities.
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